Insider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) Director Sells 1,666 Shares of Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) Director Vicki L. Sato sold 1,666 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $19.13, for a total transaction of $31,870.58. Following the completion of the transaction, the director now owns 126,373 shares of the company’s stock, valued at approximately $2,417,515.49. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Denali Therapeutics Stock Up 3.5 %

Shares of DNLI stock opened at $18.76 on Friday. The company has a market cap of $2.59 billion, a price-to-earnings ratio of -19.34 and a beta of 1.19. Denali Therapeutics Inc. has a 52 week low of $15.45 and a 52 week high of $33.31. The firm has a 50 day moving average of $20.47 and a 200-day moving average of $25.36.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Tuesday, November 7th. The company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.09. The company had revenue of $1.30 million during the quarter, compared to the consensus estimate of $11.16 million. Denali Therapeutics had a negative net margin of 36.51% and a negative return on equity of 11.54%. The company’s quarterly revenue was down 63.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.84) EPS. Analysts anticipate that Denali Therapeutics Inc. will post -1.03 earnings per share for the current year.

Institutional Trading of Denali Therapeutics

Large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. lifted its holdings in shares of Denali Therapeutics by 17.1% in the 1st quarter. JPMorgan Chase & Co. now owns 97,372 shares of the company’s stock worth $3,133,000 after purchasing an additional 14,227 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in shares of Denali Therapeutics by 55.6% in the 1st quarter. MetLife Investment Management LLC now owns 50,392 shares of the company’s stock worth $1,621,000 after purchasing an additional 18,003 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Denali Therapeutics by 0.5% in the 1st quarter. Rhumbline Advisers now owns 97,145 shares of the company’s stock worth $3,125,000 after purchasing an additional 496 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Denali Therapeutics by 0.9% in the 1st quarter. BlackRock Inc. now owns 8,185,740 shares of the company’s stock worth $263,336,000 after purchasing an additional 74,918 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Denali Therapeutics by 13.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 878,224 shares of the company’s stock worth $28,253,000 after purchasing an additional 106,027 shares in the last quarter. Institutional investors and hedge funds own 78.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on DNLI shares. HC Wainwright reiterated a “buy” rating and issued a $105.00 price objective on shares of Denali Therapeutics in a report on Thursday, August 31st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $35.00 price objective (down previously from $85.00) on shares of Denali Therapeutics in a report on Tuesday, October 24th. Wedbush reiterated an “outperform” rating and issued a $31.00 price objective on shares of Denali Therapeutics in a report on Wednesday, November 8th. TheStreet lowered shares of Denali Therapeutics from a “c-” rating to a “d+” rating in a report on Wednesday, September 6th. Finally, B. Riley began coverage on shares of Denali Therapeutics in a research report on Wednesday, September 6th. They set a “buy” rating and a $38.00 target price for the company. Eleven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $52.20.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, developing a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases. It pursues new treatments by assessing genetically validated targets, engineering delivery across the blood-brain barrier, and guiding development through biomarkers that demonstrate target and pathway engagement.